Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

452
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
452
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

639
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
639
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

705
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
705
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

525
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
525
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

899
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
899
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

702
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
702

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iptacopan in IgA Nephropathy - Final 24-Month Data.

The New England journal of medicine·2026
Same author

The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats.

International journal of molecular sciences·2023
Same author

Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution.

Cell reports. Medicine·2023
Same author

Author Correction: Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits.

Nature communications·2023
Same author

BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor.

Journal of medicinal chemistry·2022
Same author

Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits.

Nature communications·2022

Related Experiment Video

Updated: Mar 16, 2026

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

2.0K

Con: STOP immunosuppression in IgA nephropathy.

Thomas Rauen1, Frank Eitner1,2, Christina Fitzner3

  • 1Department of Nephrology, RWTH University of Aachen, Aachen, Germany.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|August 13, 2016
PubMed
Summary

Immunosuppression in IgA nephropathy (IgAN) showed higher remission rates but did not improve long-term kidney function compared to supportive care alone in high-risk patients.

Keywords:
IgA nephropathyend-stage renal diseaseglomerulonephritisimmunosuppressionproteinuria

More Related Videos

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

2.2K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.4K

Related Experiment Videos

Last Updated: Mar 16, 2026

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

2.0K
Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

2.2K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.4K

Area of Science:

  • Nephrology
  • Immunology
  • Clinical Trials

Background:

  • Immunoglobulin A nephropathy (IgAN) is a leading cause of chronic kidney disease.
  • Supportive care is the primary treatment, but progressive disease necessitates exploring other options.
  • The STOP-IgAN trial investigated immunosuppression in high-risk IgAN patients.

Purpose of the Study:

  • To evaluate the efficacy of adding immunosuppression to supportive care for IgAN patients at high risk of disease progression.
  • To assess the impact on renal endpoints, including estimated glomerular filtration rate (eGFR) and proteinuria.

Main Methods:

  • Randomized controlled trial (STOP-IgAN) comparing supportive care with supportive care plus immunosuppression.
  • Inclusion of high-risk IgAN patients with potential for progressive disease.
  • 3-year follow-up assessing renal function decline and proteinuria levels.

Main Results:

  • Immunosuppressed patients had higher rates of full clinical remission and transient proteinuria reduction.
  • Renal function deterioration (eGFR decrease) was slow in both groups and not significantly affected by immunosuppression.
  • Lower baseline proteinuria predicted clinical remission, but the proteinuria drop in the immunosuppressed group did not translate to improved long-term renal outcomes.

Conclusions:

  • Adding immunosuppression to supportive care in high-risk IgAN patients did not demonstrate a significant benefit in slowing renal function decline over 3 years.
  • While short-term improvements in remission and proteinuria were observed, long-term renal outcomes were similar between groups.
  • Further studies are needed for specific IgAN patient subgroups with rapidly progressing disease or persistent heavy proteinuria.